Annual Report

Overview

The report describes the company's successful initiation of the Phase 3 Serenta trial of eRapa in FAP during 2025, alongside continued development of its clinical-stage pipeline. It reports no revenue for the year and a Group workforce of 11 employees. The environmental disclosure reports location-based Scope 2 emissions of 10 Tonnes CO2e and Scope 3 emissions of 1 Tonnes CO2e, with a reported total of 12 Tonnes CO2e.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 27 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services